Clinical Trial: NCT03778229
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-04-23 |
Study Overview
Brief Summary
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib
Official Title
A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.
Conditions
Carcinoma
Intervention / Treatment
- Drug: osimertinib
- Drug: savolitinib
- Drug: placebo
Other Study ID Numbers
- D5084C00007
- 2018-003012-51
- 2018
Start Date (Actual)
2019-01-09
Primary Completion Date (Actual)
2024-08-23
Study Completion Date (Estimated)
2026-12-31
Enrollment (Actual)
367
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-04-23 |
Study Overview
Brief Summary
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib
Official Title
A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.
Conditions
Carcinoma
Intervention / Treatment
- Drug: osimertinib
- Drug: savolitinib
- Drug: placebo
Other Study ID Numbers
- D5084C00007
- 2018-003012-51
- 2018
Start Date (Actual)
2019-01-09
Primary Completion Date (Actual)
2024-08-23
Study Completion Date (Estimated)
2026-12-31
Enrollment (Actual)
367
Study Type
Interventional
Phase
Phase 2